{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:48:01Z","timestamp":1740124081651,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11102-023-01320-9","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T07:02:33Z","timestamp":1682665353000},"page":"303-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Medical therapy for refractory pituitary adenomas"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-1889","authenticated-orcid":false,"given":"Eliza B.","family":"Geer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"6","key":"1320_CR1","first-page":"300","volume":"62","author":"LA Casulari","year":"2004","unstructured":"Casulari LA et al (2004) Nelson\u2019s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62(6):300\u2013305","journal-title":"Horm Res"},{"issue":"5","key":"1320_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1210\/jc.2013-1497","volume":"98","author":"L Katznelson","year":"2013","unstructured":"Katznelson L (2013) Sustained improvements in plasma ACTH and clinical status in a patient with Nelson\u2019s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. J Clin Endocrinol Metab 98(5):1803\u20131807","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1320_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11102-017-0853-3","volume":"21","author":"E Daniel","year":"2018","unstructured":"Daniel E et al (2018) A prospective longitudinal study of Pasireotide in Nelson\u2019s syndrome. Pituitary 21(3):247\u2013255","journal-title":"Pituitary"},{"issue":"2","key":"1320_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ando.2018.07.013","volume":"80","author":"H Lasolle","year":"2019","unstructured":"Lasolle H et al (2019) Pasireotide: a potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris) 80(2):84\u201388","journal-title":"Ann Endocrinol (Paris)"},{"key":"1320_CR5","doi-asserted-by":"crossref","unstructured":"Coopmans EC et al (2019) Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.Eur J Endocrinol, 181(2): p. K21-K27.","DOI":"10.1530\/EJE-19-0279"},{"issue":"4","key":"1320_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11102-008-0162-y","volume":"14","author":"A Fusco","year":"2011","unstructured":"Fusco A et al (2011) Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary 14(4):351\u2013357","journal-title":"Pituitary"},{"issue":"3","key":"1320_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a european Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265\u2013276","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1320_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593\u2013605","journal-title":"Eur J Endocrinol"},{"key":"1320_CR9","doi-asserted-by":"publisher","first-page":"700007","DOI":"10.3389\/fneur.2021.700007","volume":"12","author":"M Luo","year":"2021","unstructured":"Luo M et al (2021) Clinical efficacy of Temozolomide and its predictors in aggressive pituitary tumors and Pituitary Carcinomas: a systematic review and Meta-analysis. Front Neurol 12:700007","journal-title":"Front Neurol"},{"issue":"1","key":"1320_CR10","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1\u2013G24","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1320_CR11","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689\u20131698","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1320_CR12","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2012-2924","volume":"98","author":"T Hirohata","year":"2013","unstructured":"Hirohata T et al (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130\u20131136","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1320_CR13","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL et al (2018) Marked response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. J Clin Endocrinol Metab 103(10):3925\u20133930","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1320_CR14","doi-asserted-by":"publisher","first-page":"bvab133","DOI":"10.1210\/jendso\/bvab133","volume":"5","author":"AL Lin","year":"2021","unstructured":"Lin AL et al (2021) Synergism of checkpoint inhibitors and peptide receptor Radionuclide Therapy in the treatment of Pituitary Carcinoma. J Endocr Soc 5(10):bvab133","journal-title":"J Endocr Soc"},{"issue":"1","key":"1320_CR15","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-20-0151","volume":"184","author":"B Sol","year":"2021","unstructured":"Sol B et al (2021) Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment? Eur J Endocrinol 184(1):K1\u2013K5","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1320_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","volume":"31","author":"M Caccese","year":"2020","unstructured":"Caccese M et al (2020) Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anticancer Drugs 31(2):199\u2013204","journal-title":"Anticancer Drugs"},{"key":"1320_CR17","doi-asserted-by":"publisher","first-page":"576027","DOI":"10.3389\/fendo.2020.576027","volume":"11","author":"LS Lamb","year":"2020","unstructured":"Lamb LS, Sim HW, McCormack AI (2020) Case Report: a case of Pituitary Carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy. Front Endocrinol (Lausanne) 11:576027","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1320_CR18","doi-asserted-by":"crossref","unstructured":"Majd N et al (2020) Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study.J Immunother Cancer, 8(2)","DOI":"10.1136\/jitc-2020-001532"},{"issue":"5","key":"1320_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1530\/EJE-22-0647","volume":"187","author":"MD Ilie","year":"2022","unstructured":"Ilie MD et al (2022) Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Eur J Endocrinol 187(5):685\u2013696","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1320_CR20","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","volume":"91","author":"S Shah","year":"2022","unstructured":"Shah S et al (2022) Complete response of a patient with a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune checkpoint inhibitor therapy: a Case Report. Neurosurgery 91(2):e51\u2013e56","journal-title":"Neurosurgery"},{"key":"1320_CR21","doi-asserted-by":"crossref","unstructured":"Duhamel C et al (2020) Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: two case reports and a review of the literature.J Pers Med, 10(3)","DOI":"10.3390\/jpm10030088"},{"key":"1320_CR22","doi-asserted-by":"crossref","unstructured":"Goichot B et al (2021) Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy. Clin Endocrinol (Oxf)","DOI":"10.1111\/cen.14645"},{"key":"1320_CR23","doi-asserted-by":"crossref","unstructured":"Raverot G, Ilie MD (2022) Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.Best Pract Res Clin Endocrinol Metab, : p.101712","DOI":"10.1016\/j.beem.2022.101712"},{"issue":"2","key":"1320_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12020-013-0093-x","volume":"46","author":"O Cooper","year":"2014","unstructured":"Cooper O et al (2014) Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine 46(2):318\u2013327","journal-title":"Endocrine"},{"issue":"2","key":"1320_CR25","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O et al (2021) EGFR\/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. J Clin Endocrinol Metab 106(2):e917\u2013e925","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1320_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2018-02461","volume":"104","author":"D Zhang","year":"2019","unstructured":"Zhang D et al (2019) Effect of Everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 104(6):1929\u20131936","journal-title":"J Clin Endocrinol Metab"},{"key":"1320_CR27","doi-asserted-by":"crossref","unstructured":"Cornell RF et al (2013) Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency Case Rep Endocrinol, 2013: p.\u00a0675298","DOI":"10.1155\/2013\/675298"},{"key":"1320_CR28","doi-asserted-by":"publisher","first-page":"784889","DOI":"10.3389\/fendo.2021.784889","volume":"12","author":"P Remon-Ruiz","year":"2021","unstructured":"Remon-Ruiz P et al (2021) A Silent Corticotroph Pituitary Carcinoma: Lessons from an exceptional case report. Front Endocrinol (Lausanne) 12:784889","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01320-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:25:11Z","timestamp":1688981111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01320-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01320-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"type":"print","value":"1386-341X"},{"type":"electronic","value":"1573-7403"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"11 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}